ライフサイエンスコーパス: negative symptom

1 sity, and anhedonia, as well as parent-rated negative symptoms).

2 schizophrenia, with the potential to address negative symptoms.

3 MCCB scores were inversely correlated with negative symptoms.

4 ed periods of moderate to severe positive or negative symptoms.

5 lity for increasing severity of parent-rated negative symptoms.

6 associated with schizophrenia in particular negative symptoms.

7 istinguished EOS patients with predominantly negative symptoms.

8 mpal activity was positively correlated with negative symptoms.

9 e self-rated scales and 17% for parent-rated negative symptoms.

10 etween hippocampal activity and positive and negative symptoms.

11 logy of schizophrenia and, in particular, of negative symptoms.

12 lized medicine approach for the treatment of negative symptoms.

13 s were greatest among patients with elevated negative symptoms.

14 oms: the more the volume reduction, the more negative symptoms.

15 pirically developed and evaluated measure of negative symptoms.

16 riprazine in adult patients with predominant negative symptoms.

17 related with the severity of a participant's negative symptoms.

18 lated with the severity of both positive and negative symptoms.

19 herwise different in patients with prominent negative symptoms.

20 whether these deficits were associated with negative symptoms.

21 measured by the Scale for the Assessment of Negative Symptoms.

22 nal alterations was unrelated to severity of negative symptoms.

23 ined sceptical as to its potential to reduce negative symptoms.

24 of auditory verbal hallucinations as well as negative symptoms.

25 everal of these abnormalities were linked to negative symptoms.

26 nia and the relationship between smoking and negative symptoms.

27 last week, compared with those with moderate negative symptoms.

28 choline receptor system for the treatment of negative symptoms.

29 her evaluation of behavioural activation for negative symptoms.

30 inic acetylcholine receptor availability and negative symptoms.

31 outcome via impaired cognition and increased negative symptoms.

32 rmal activation correlated with positive and negative symptoms.

33 ts operant performance, a potential index of negative symptoms.

34 y in people with schizophrenia and prominent negative symptoms.

35 otype would be significantly associated with negative symptoms.

36 t is most pronounced in patients with severe negative symptoms.

37 oved efficacy in the treatment of persistent negative symptoms.

38 tween the presence of the risk haplotype and negative symptoms.

39 mediodorsal nucleus was associated with more negative symptoms.

40 the two drugs in their effect on positive or negative symptoms.

41 plications for the treatment of positive and negative symptoms.

42 y correlated with the SANS global ratings of negative symptoms.

43 et or ratings of disorganized, psychotic, or negative symptoms.

44 F volumes than the epilepsy patients without negative symptoms.

45 Symptoms and the Scale for the Assessment of Negative Symptoms.

46 ozapine was the most effective treatment for negative symptoms.

47 broad range of symptoms but do not extend to negative symptoms.

48 haloperidol and risperidone for reduction of negative symptoms.

49 er, a trend toward an effect was observed on negative symptoms.

50 separate pathways that involved or bypassed negative symptoms.

51 the latter accounting for 37% of variance in negative symptoms.

52 rking memory than patients without prominent negative symptoms.

53 ited, 29 were classified as having prominent negative symptoms.

54 could be distinguished by NSS and prominent negative symptoms.

55 y resemble those of schizophrenia, including negative symptoms.

56 nd total NSS than patients without prominent negative symptoms.

57 ore illness domains: psychosis and cognitive/negative symptoms.

58 analysis revealed significant improvement of negative symptoms.

59 st shared environment for hallucinations and negative symptoms (17%-24%) and significant nonshared en

60 post hoc analysis of patients with moderate negative symptoms, 5 and 50 mg RG3487 vs placebo signifi

61 the MCCB; however, in patients with moderate negative symptoms, a post hoc analysis revealed signific

62 patients with schizophrenia and predominant negative symptoms across 66 sites worldwide.

63 edicted interpersonal and work skills, while negative symptoms affected interpersonal skills independ

64 t that long-lasting adaptations in LHb shape negative symptoms after drug taking.

65 r, as well as with attenuated improvement in negative symptoms after olanzapine treatment.

66 in schizophrenic subjects with predominantly negative symptoms (alogia, affective flattening, avoliti

67 patients with schizophrenia with predominant negative symptoms and a high-degree of illness severity

68 equired concurrent remission of positive and negative symptoms and adequate social/vocational functio

69 ymorphisms associated with schizophrenia and negative symptoms and anxiety disorder but not with psyc

70 etic stimulation (rTMS) for the treatment of negative symptoms and call for adequately powered multic

71 nique pharmacological profile for addressing negative symptoms and cognitive deficits in schizophreni

72 lizumab, would improve residual positive and negative symptoms and cognitive deficits in schizophreni

73 ypically have minimal therapeutic effects on negative symptoms and cognitive deficits.

74 onstrated encouraging results on measures of negative symptoms and cognitive dysfunction in schizophr

75 et medical needs remain for the treatment of negative symptoms and cognitive dysfunction.

76 aily living after the analysis accounted for negative symptoms and cognitive functions.

77 sode schizophrenia and its relationship with negative symptoms and cognitive functions.

78 ysiology of schizophrenia, especially of the negative symptoms and cognitive impairments associated w

79 s with schizophrenia frequently present with negative symptoms and cognitive impairments for which no

80 promising treatments for moderate to severe negative symptoms and cognitive impairments.

81 ed significantly worse than patients without negative symptoms and comparison subjects across measure

82 nia, depression, positive symptoms, anxiety, negative symptoms and disorganization.

83 Ketamine produced negative symptoms and disrupted delayed recall.

84 t in activities could lead to improvement in negative symptoms and function, but few trials have been

85 atistically significant efficacy in reducing negative symptoms and good tolerability in stable schizo

86 Higher levels of negative symptoms and hostility are specifically associa

87 tance of developing effective treatments for negative symptoms and hostility in order to improve the

88 Low levels of negative symptoms and hostility were significantly assoc

89 sychosis, poor premorbid functioning, stable negative symptoms and impaired social cognition and neur

90 being highest for paranoia and parent-rated negative symptoms and lowest for hallucinations.

91 ssions to support activation for people with negative symptoms and mental health professional pessimi

92 etrieval accuracy negatively correlated with negative symptoms and no-retrieval accuracy negatively c

93 blunted ERN was associated with more severe negative symptoms and poorer real-world functioning, as

94 sponses for relevant stimuli help to explain negative symptoms and provide a unified explanation for

95 basic needs, were unemployed, and had severe negative symptoms and severe formal thought disorder.

96 relationship, if it is associated with both negative symptoms and SIDs.

97 rienced similar improvements in positive and negative symptoms and similar risks of psychotic exacerb

98 The SIDs have been linked with negative symptoms and the deficit syndrome, but any spec

99 The SIDs were related to negative symptoms and the deficit syndrome, but the asso

100 everity from the Scale for the Assessment of Negative Symptoms and the Scale for the Assessment of Po

101 re scores on the Scale for the Assessment of Negative Symptoms and the Scale for the Assessment of Po

102 gions is associated with a greater number of negative symptoms and worse performance on tests of exec

103 Symptoms and the Scale for the Assessment of Negative Symptoms, and affective symptoms were assessed

104 These data suggest that although cognition, negative symptoms, and age are important discriminators

105 arsed into three domains: positive symptoms, negative symptoms, and cognitive deficits.

106 matology characterized by positive symptoms, negative symptoms, and cognitive impairment.

107 s before clinic entry, baseline functioning, negative symptoms, and disorders of thought content.

108 amine the associations among EAP, cognition, negative symptoms, and functional outcome.

109 Symptoms and the Scale for the Assessment of Negative Symptoms, and volumetric measurements of the en

110 ammatory state, its association with primary negative symptoms, and whether there are significant dif

111 ith regard to dwelling status, cognition and negative symptoms appear to have the strongest impact.

112 The effects on depressive and negative symptoms appeared more pronounced when minimum

113 phrenia, likely contributing to positive and negative symptoms as well as impaired cognition.

114 A measure of negative symptoms (as opposed to deficit schizophrenia)

115 IDs in schizophrenia were related broadly to negative symptoms, as are a number of other neuropsychol

116 etiology characterized by both positive and negative symptoms, as well as cognitive deficits.

117 dary outcomes were change in MCCB domain and negative symptom assessment (NSA) scores.

118 provement was seen at week 24 on the 16-item Negative Symptom Assessment Scale total score for ABT-12

119 contribute to the emergence of positive and negative symptoms associated with schizophrenia.

120 otogenic action, producing both positive and negative symptoms associated with schizophrenia.

121 hypofunction and the cognitive deficits and negative symptoms associated with this disease.

122 cognitive symptoms, but not the positive or negative symptoms, associated with schizophrenia.

123 npsychotic disorder was associated with more negative symptoms at baseline.

124 itive dysfunction is commonly accompanied by negative symptoms (avolition, alogia, and affective flat

125 P < .001), cognition had a direct effect on negative symptoms (beta = -0.16, P < .001), and both cog

126 ion (beta = 0.26, P < .001) and experiential negative symptoms (beta = -0.75, P < .001) had direct ef

127 lly significant difference in improvement in negative symptoms between the two groups at day 21 (p =

128 Patients were also assessed for severity of negative symptoms by using the Schedule for the Assessme

129 ptoms, the Clinical Assessment Interview for Negative Symptoms (CAINS) was developed using an iterati

130 drome Scale (PANSS), Scale for Assessment of Negative Symptoms, Calgary Depression Scale for Schizoph

131 Correlates of psychosis, cognitive and negative symptoms can be found in white matter.

132 condary outcomes were change in positive and negative symptoms, categorical response to treatment, st

133 Functional status, negative symptoms, cognitive functions, and health statu

134 om Interview at 12 and 18 years of age), (2) negative symptoms (Community Assessment of Psychic Exper

135 the paranoid subtype or to have less severe negative symptoms compared with EOS patients.

136 ns remain regarding its efficacy for primary negative symptoms, comparison with a moderate dose of a

137 NC=0.04 vs dDC-NC=-0.49, p=0.008) but not on negative symptoms (dCC-NC=-0.09 vs dDC-NC=-0.31, p=0.41)

138 itional functional deficits in patients with negative symptoms, deficits which may explain the accomp

139 hrenia appears to be manifest as anxiety and negative symptoms during adolescence, a greater focus on

140 more severe in patients with high scores of negative symptoms during reward anticipation (r = -0.41;

141 ria for either residual positive or residual negative symptoms entered a 16-week double-blind, parall

142 The epilepsy patients with negative symptoms exhibited significantly greater diffus

143 Patients with prominent negative symptoms exhibited significantly more motor coo

144 ched significance only in the alleviation of negative symptoms from an antipsychotic-free baseline (P

145 t differentiated subjects with predominantly negative symptoms from those with predominantly positive

146 clinical features (i.e., positive symptoms, negative symptoms, functional deficits).

147 s significantly more efficacious in reducing negative symptoms (g=0.27).

148 neuropsychological functions, the prominent negative symptoms group still exhibited poorer motor coo

149 year), stable schizophrenia and predominant negative symptoms (>6 months) at 66 study centres (mainl

150 Patients with prominent negative symptoms had greater regional alterations in br

151 t twice as many patients with absent or mild negative symptoms had met a friend in the last week, com

152 The subjects with predominantly negative symptoms had significant differences in glucose

153 The epilepsy patients with and without negative symptoms had statistically equivalent Beck Depr

154 A major barrier to developing treatments for negative symptoms has been measurement concerns with exi

155 Schizophrenic subjects with predominantly negative symptoms have greater metabolic abnormalities t

156 Negative symptoms have previously been associated with r

157 4 years to determine levels of positive and negative symptoms, impairment in activities of daily liv

158 Apathy is a common negative symptom in schizophrenia.

159 BP1 risk haplotype and a lifetime history of negative symptoms in 181 Caucasian patients with schizop

160 We aimed to assess effects of D-serine on negative symptoms in at risk individuals.

161 ive striatum correlated with inattention and negative symptoms in CD, and with poorer working memory

162 with decreased goal-directed task effort and negative symptoms in consumers with schizophrenia was in

163 ists produce schizophrenia-like positive and negative symptoms in healthy human subjects.

164 ave robust efficacy in treating positive and negative symptoms in patients with schizophrenia.

165 BP1 genetic variation may be associated with negative symptoms in patients with schizophrenia.

166 disorder and healthy control subjects and to negative symptoms in patients with schizophrenia.

167 differential benefit for either positive or negative symptoms in patients with treatment-resistant s

168 e was support for behavioural activation for negative symptoms in psychosis from some mental health w

169 tors, the difficulty in engaging people with negative symptoms in psychosocial treatments and service

170 afe, and well tolerated for the positive and negative symptoms in schizophrenia and schizoaffective d

171 are urgently searching for options to treat negative symptoms in schizophrenia because these symptom

172 s could underlie anhedonia in depression and negative symptoms in schizophrenia by disrupting learnin

173 The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST) was a

174 rtial agonists for cognitive dysfunction and negative symptoms in schizophrenia.

175 egion may be associated with the severity of negative symptoms in schizophrenia.

176 k effort indexed by pupillary responses, and negative symptoms in schizophrenia.

177 that may contribute to diminished effort and negative symptoms in schizophrenia.

178 ntal cortex for the treatment of predominant negative symptoms in schizophrenia.

179 ties, in comparison with placebo in treating negative symptoms in stabilized patients with schizophre

180 onist, TC-5619, on cognitive dysfunction and negative symptoms in subjects with schizophrenia.

181 s associated with a significant reduction of negative symptoms in the 10-mg/d (mean [SE] reduction in

182 Antisaccade errors were correlated with negative symptoms in the patients.

183 mptoms performed worse than patients without negative symptoms in working memory functions but not ot

184 Negative symptoms, independent of structural volumes, pr

185 In schizophrenia, the severity of negative symptoms is a key predictor of long-term disabi

186 altered effort allocation to the severity of negative symptoms is mixed.

187 py on prodromal states, acute schizophrenia, negative symptoms, loss of insight and relapse preventio

188 and paroxysmal positive symptoms as well as negative symptoms may be a consequence of varying degree

189 inic acetylcholine receptor availability and negative symptoms may explain the high rates of smoking

190 Reduction of cognitive deficits and negative symptoms may improve patients' ability to funct

191 y matter observed in patients with prominent negative symptoms may provide unique insight into the ea

192 ailability was also strongly correlated with negative symptoms measured using the Positive and Negati

193 dity was demonstrated by linkages with other negative symptom measures, self-report scales of sociali

194 dence-based treatment for depression, to the negative symptoms observed in psychosis from the perspec

195 set P </= .05 threshold were associated with negative symptoms (odds ratio [OR] per SD increase in PR

196 n hedonic responses that are relevant to the negative symptoms of disorders such as schizophrenia.

197 is defined by core symptoms in two domains: negative symptoms of impairment in social and communicat

198 clude art therapy, are considered to improve negative symptoms of psychosis.

199 Negative symptoms of schizophrenia (NSS), related to hyp

200 nAChR availability was associated with lower negative symptoms of schizophrenia and better performanc

201 Although predominant negative symptoms of schizophrenia can be severe enough

202 ignificant improvements in both positive and negative symptoms of schizophrenia compared to placebo (

203 tive effects across cognitive, positive, and negative symptoms of schizophrenia in animal models and

204 agonist prodrug decreased both positive and negative symptoms of schizophrenia raised hopes that glu

205 , and clinical studies have revealed reduced negative symptoms of schizophrenia with a dose of pregne

206 nderlying social withdrawal, one of the core negative symptoms of schizophrenia, are not well underst

207 onia in depression and both the positive and negative symptoms of schizophrenia, but it remains uncle

208 plus vitamin B12 supplementation can improve negative symptoms of schizophrenia, but treatment respon

209 ary outcomes included change in positive and negative symptoms of schizophrenia, categorical response

210 tal signaling appears blunted in MDD and the negative symptoms of schizophrenia, elevated in bipolar

211 More effective treatments are needed for negative symptoms of schizophrenia, which are typically

212 rically focused on reducing the positive and negative symptoms of schizophrenia, with recent increase

213 that changes in D3Rs may be involved in the negative symptoms of schizophrenia.

214 ynaptic plasticity and thereby might improve negative symptoms of schizophrenia.

215 s a treatment for the cognitive deficits and negative symptoms of schizophrenia.

216 ess striatal D2 receptors (D2R-OE) model the negative symptoms of schizophrenia.

217 ntipsychotic drugs for treating positive and negative symptoms of schizophrenia.

218 wal behaviors that may have relevance to the negative symptoms of schizophrenia.

219 s as potential new treatments for persistent negative symptoms of schizophrenia.

220 e improved overall symptoms and positive and negative symptoms of schizophrenia.

221 rior frontal white matter are related to the negative symptoms of schizophrenia.

222 -prefrontal circuits, which may underlie the negative symptoms of schizophrenia.

223 d experience of patients with the persistent negative symptoms of schizophrenia.

224 cariprazine in the treatment of predominant negative symptoms of schizophrenia.

225 ly effective therapeutic option for treating negative symptoms or cognitive impairments.

226 Negative symptom outcomes and measures of parkinsonism a

227 ncluding total symptoms, depression/anxiety, negative symptoms, overall functioning, positive symptom

228 tcome measures (e.g., pervasive positive and negative symptoms, overall social functioning, and abili

229 and Negative Syndrome Scale factor score for negative symptoms (PANSS-FSNS) analysed in a modified in

230 parison subjects, the epilepsy patients with negative symptoms performed significantly worse than pat

231 Patients with prominent negative symptoms performed worse than patients without

232 reliable measures of diagnosis, positive and negative symptoms, periods of untreated psychosis and pr

233 Depressive and negative symptoms (primary outcomes), overall symptoms,

234 x were associated with a greater severity of negative symptoms (r=0.42; P=0.017) and a lower level of

235 25) on sensitivity as well as of positive-to-negative symptom ratio (p=0.022) and antipsychotic medic

236 t of which have been shown to correlate with negative symptoms: reduced learning from rewards; blunte

237 rons to electrophysiological, cognitive, and negative-symptom-related behavioral phenotypes of schizo

238 des showed significantly greater severity of negative symptoms relative to consumers with mild defeat

239 , and core pathologies such as cognition and negative symptom remain unmet therapeutic challenges.

240 Disagreement was defined as a negative symptom report or no mention of a symptom in th

241 ontal cortex could affect hallucinations and negative symptoms, respectively.

242 ween brain structure volume and positive and negative symptom response to clozapine and haloperidol.

243 (range, 24-168), Scale for the Assessment of Negative Symptoms (SANS) (range, 0-125), Montgomery-Asbe

244 effects, and the Scale for the Assessment of Negative Symptoms (SANS) and Brief Psychiatric Rating Sc

245 The Scale for the Assessment of Negative Symptoms (SANS) and the Brief Psychiatric Ratin

246 te of change" of Scale for the Assessment of Negative Symptoms (SANS) total scores and change in the

247 e (BPRS) and the Scale for the Assessment of Negative Symptoms (SANS), among other measures.

248 ating Scale, the Scale for the Assessment of Negative Symptoms (SANS), the Geriatric Depression Scale

249 by using the Schedule for the Assessment of Negative Symptoms (SANS).

250 CSB composite score; Scale for Assessment of Negative Symptoms (SANS); Clinical Global Impression-Glo

251 luded a modified Scale for the Assessment of Negative Symptoms (SANS-18) and Positive and Negative Sy

252 Negative Syndrome Scale (PANSS) and a PANSS negative symptom scale that eliminated items that most o

253 al Global Impressions Scale (CGI), the Brief Negative Symptom Scale, the Brief Assessment of Cognitio

254 scores, the CGI severity item, and the Brief Negative Symptom Scale.

255 The key predictor of total positive and negative symptom score was greater in the primary psycho

256 ptoms in the 10-mg/d (mean [SE] reduction in negative symptoms score, -25% [2%]; P = .049) and 30-mg/

257 Patients' BPRS total, positive, and negative symptom scores significantly increased during p

258 Negative symptom scores were significantly worse in the

259 Improvements seen in total and negative symptom scores with clozapine and olanzapine we

260 e was associated with greater BPRS total and negative symptom scores.

261 signal abnormalities did not correlate with negative symptom severity in schizophrenia.

262 rd pairs; this underretrieval increased with negative symptom severity.

263 al fluid volume were associated with greater negative symptom severity.

264 ormance, functional capacity, or positive or negative symptom severity.

265 In addition, patients with negative symptoms showed impaired behavioural performanc

266 Folate plus vitamin B12 improved negative symptoms significantly compared with placebo (g

267 itive symptoms (SMD 0.45) improved more than negative symptoms (SMD 0.35) and depression (SMD 0.27).

268 n difference: -0.25, 95% CI=-0.38 to -0.12), negative symptoms (standardized mean difference: -0.30,

269 Negative symptom subjects had a lower glucose metabolic

270 Negative symptom subscale scores were negatively correla

271 nd working memory, as well as improvement in negative symptoms such as anhedonia and alogia.

272 ucinations, delusions and thought disorder), negative symptoms (such as social withdrawal, apathy and

273 network of regions predicted the severity of negative symptoms, such as impoverished speech and flatt

274 Analysis of primary outcomes (depressive and negative symptoms) suggests small, beneficial effects of

275 ing psychosis was also associated with fewer negative symptoms than other remitting psychoses.

276 inic receptors, improved clinical ratings of negative symptoms that are generally resistant to treatm

277 Health's Consensus Development Conference on Negative Symptoms, the Clinical Assessment Interview for

278 strikingly and significantly correlated with negative symptoms: the more the volume reduction, the mo

279 uperior compared with sham rTMS in improving negative symptoms; this is in contrast to findings from

280 d inversely with the Scale for Assessment of Negative Symptoms total score and was lower in patients

281 econdary outcome measures, such as the PANSS negative symptom, total, and activation factor scores, t

282 Secondary outcomes included positive and negative symptoms, treatment recommendations by authors,

283 Improvements in positive and negative symptoms were also significantly greater in pat

284 At intake and follow-up, positive and negative symptoms were assessed with the Scale for the A

285 Negative symptoms were independent of current and past d

286 Negative symptoms were measured by the Scale for the Ass

287 Rating Scale memory subscale and more severe negative symptoms were significantly associated with wor

288 consumers with mild defeatist attitudes and negative symptoms were significantly correlated with def

289 Negative symptoms were significantly more prevalent in t

290 el for binary data showed that the prominent negative symptoms were stable over time.

291 he PANSS and the Scale for the Assessment of Negative Symptoms were used.

292 of olanzapine over haloperidol in improving negative symptoms when the PANSS and the Scale for the A

293 ate highly significant beneficial effects on negative symptoms when these compounds are added to both

294 al psychopathology, thought disturbance, and negative symptoms, whereas patients carrying the G allel

295 y symptoms, cognitive impairment, and severe negative symptoms, which impair functioning and require

296 ine induced a 35.7% (SD 17.8) improvement in negative symptoms, which was significant compared with p

297 Collectively, a subset of negative symptoms with a reduced willingness to expend c

298 prospective criteria for moderate to severe negative symptoms without marked positive, depressive, o

299 associated with significant improvements in negative symptoms without positive symptom worsening.

300 inuation was not associated with positive or negative symptom worsening.